Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
The phase III POD1UM-304 study is evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer (NSCLC) not harboring a driver mutation. The POD1UM-304 study met the primary endpoint of overall survival (OS) and all secondary endpoints in patients with previously untreated metastatic NSCLC. Shares of Incyte have risen 20.9% year to date against the industry's 7.5% decline. Image Source: Zacks Investment Research Results from the POD1UM-304 study showed a clinically meaningful and statistically significant improvement over chemotherapy alone. Patients in the retifanlimab and chemotherapy combination treatment group achieved a median OS of 18.1 months compared to 13.4 months in the placebo and chemotherapy combination group. The study also met secondary endpoints. Patients who received retifanlimab in combination with chemotherapy had a two-month i
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Wells Fargo & Company from $68.00 to $70.00. They now have an "equal weight" rating on the stock.MarketBeat
- Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCYAccesswire
- Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCYAccesswire
- Incyte Co. (NASDAQ: INCY) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $77.00 price target on the stock.MarketBeat
- Incyte to Present at Upcoming Investor ConferenceBusiness Wire
INCY
Earnings
- 10/29/24 - Beat
INCY
Sec Filings
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- INCY's page on the SEC website